By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is bearish on Waystar (WAY) due to AI-driven margin compression, regulatory hurdles, and potential capital allocation risks. The stock's significant discount and slowdown in growth are seen as insufficient to offset these threats.
Risk: AI-driven margin compression and potential capital allocation risks
Opportunity: Payer consolidation potentially locking in longer renewals if Waystar's data moat translates into superior retention and price-upsell
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for “Meridian Growth Fund”. A copy of the letter can be downloaded here. The US equity market started 2026 with volatility due to trade policy uncertainty and geopolitical risks. Initial optimism from domestic company confidence and the Federal Reserve easing waned following increased tariffs and military strikes against Iran. The value outperformed across the entire market-cap spectrum. Against this backdrop, the Meridian Growth Fund (the “Fund”) returned -7.90%, trailing the Russell 2500 Growth Index benchmark, which returned -3.52%. The underperformance was driven by industry allocation effects, while stock selection was a meaningful positive contributor. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Meridian Growth Fund highlighted Waystar Holding Corp. (NASDAQ:WAY). Waystar Holding Corp. (NASDAQ:WAY) is a technology company that provides software solutions for healthcare payments. On May 21, 2026, Waystar Holding Corp. (NASDAQ:WAY) closed at $18.84 per share. One-month return of Waystar Holding Corp. (NASDAQ:WAY) was -24.55%, and its shares lost 50.34% over the past 52 weeks. Waystar Holding Corp. (NASDAQ:WAY) has a market capitalization of $3.61 billion.
Meridian Growth Fund stated the following regarding Waystar Holding Corp. (NASDAQ:WAY) in its Q1 2026 investor letter:
"Waystar Holding Corp.(NASDAQ:WAY) is a leading provider of healthcare payments software, offering a cloud-based platform that simplifies revenue cycle management for healthcare providers and payers. The company benefits from deep workflow integration, proprietary data assets, and an expanding AI powered automation suite that creates meaningful switching costs. Shares declined during the quarter despite delivering a strong fourth-quarter beat, with record bookings activity and expanding margins. The selloff was driven entirely by broad market fears around AI disruption of healthcare IT companies, which we believe significantly underestimates the complexity and regulatory barriers inherent in revenue cycle workflows. We view the risk/reward as compelling at current levels."
Waystar Holding Corp. (NASDAQ:WAY) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 46 hedge fund portfolios held Waystar Holding Corp. (NASDAQ:WAY) at the end of the fourth quarter, compared to 47 in the previous quarter. In Q1 2026, Waystar Holding Corp. (NASDAQ:WAY) reported revenue of $314 million, representing 22% year-over-year growth. While we acknowledge the potential of Waystar Holding Corp. (NASDAQ:WAY) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the **best short-term AI stock**.
Four leading AI models discuss this article
"Market fears of AI disruption in healthcare payments are more justified than Meridian claims, given the risk of accelerated automation eroding WAY’s moat."
Waystar (WAY) shares fell 24.55% in a month to $18.84 after Meridian Growth Fund highlighted record Q4 bookings and 22% revenue growth, blaming the drop on generic AI disruption fears. The fund argues regulatory complexity and workflow integration create durable switching costs that generic AI tools cannot easily breach. Yet the 50% 52-week decline and slight drop in hedge-fund ownership to 46 portfolios suggest investors are pricing in faster automation of revenue-cycle tasks than Meridian admits. Broader tariff and geopolitical volatility likely amplified the move, but the core question is whether WAY’s expanding margins survive if larger cloud providers embed compliant automation layers.
The selloff could prove overdone if regulatory barriers and proprietary data truly slow AI encroachment, allowing WAY to compound at current depressed levels without margin compression.
"WAY's 50% decline suggests either genuine operational deterioration masked by Q1 beats, or a genuine mispricing—but the article provides insufficient data to distinguish between them."
WAY's 50% decline over 52 weeks and -24.55% one-month drop warrant scrutiny beyond 'AI disruption fears.' The fund claims Q1 revenue of $314M (+22% YoY) with record bookings and margin expansion, yet the stock collapsed anyway—suggesting either (1) guidance disappointed badly, (2) the market is pricing in real margin compression ahead, or (3) the selloff is genuinely irrational. At $3.61B market cap with $314M quarterly revenue (~$1.26B annualized), WAY trades at ~2.9x sales. That's not cheap for a software company facing potential AI-driven workflow automation. The fund's argument about 'complexity and regulatory barriers' protecting switching costs is reasonable but unverified here. Missing: actual margin trends, customer churn data, and whether AI is a threat to pricing power or just to labor costs (which benefits WAY if it's the automation provider).
If WAY's margins are actually compressing despite revenue growth—a sign customers are demanding price cuts due to AI commoditization—then the stock's decline reflects real deterioration, not panic. The fund may be anchoring to Q1 beats while ignoring forward guidance that signals trouble.
"Waystar’s current valuation reflects a structural shift where AI-driven commoditization of RCM workflows is eroding the long-term defensibility of their legacy software suite."
Waystar (WAY) is currently trading at a significant discount, likely pricing in terminal value concerns rather than just cyclical volatility. While Meridian highlights 'moaty' revenue cycle management (RCM) workflows, the market is aggressively discounting the stock because AI-native startups are beginning to commoditize the very billing and claims-processing tasks that constitute Waystar's core revenue. With a 50% drawdown over 52 weeks, the market is signaling that Waystar’s 22% top-line growth is insufficient to offset the threat of margin compression from AI-driven automation. Unless Waystar can pivot from a service-heavy model to a high-margin SaaS platform, the 'regulatory moat' argument is likely a value trap.
If Waystar’s proprietary data assets are as deep as claimed, they may actually be the primary beneficiaries of AI, using their existing integration to train models that competitors cannot replicate, effectively turning a disruption threat into a massive margin-expansion catalyst.
"Near-term downside risk for WAY exceeds upside as AI disruption fears, regulatory hurdles, and longer sales cycles threaten margin and revenue growth."
Waystar's drop looks like AI-disruption fear is priced in, but key risks are regulatory and budgetary. The article positions WAY as AI-enabled with high switching costs, yet healthcare revenue-cycle workflows face HIPAA/data-privacy hurdles, lengthy procurement, and payer consolidation that can suppress pricing and delay ROI. An AI-enabled entrant from a larger ERP/SaaS vendor could bundle AI with broader platforms, pressuring WAY on margins and wallet share. While WAY's Q4 beat and 22% YoY revenue growth matter, the absence of margin protection in a more competitive AI arms race and longer sales cycles could cap upside in the near term.
The countercase: AI-driven automation could accelerate WAY's ROI and renewals; WAY's data assets and integration depth could reinforce a durable moat.
"The 2.9x sales multiple already prices in AI risks, but payer-driven contract delays pose a greater unmentioned threat to growth sustainability."
Gemini's value trap warning ignores the 2.9x sales multiple Claude highlighted, which already embeds aggressive assumptions of AI-driven margin erosion. The real unaddressed risk is how HIPAA compliance timelines interact with payer consolidation: even if Waystar's workflows resist generic AI, consolidated payers could force multi-year contract renegotiations that delay revenue recognition and compress margins beyond what bookings growth suggests.
"Payer consolidation is a margin risk, but bookings growth alone doesn't prove switching costs survive pricing pressure from consolidated buyers."
Grok's payer consolidation risk is real but underspecified. The question isn't whether consolidation *happens*—it's whether WAY's switching costs actually survive it. Consolidated payers have leverage to demand price cuts or threaten to build/buy competing platforms. Bookings growth masks this if customers are locking in at lower rates. We need actual ASP (average selling price) trends and renewal rates to know if margins are genuinely protected or just deferred compression.
"Waystar's valuation is at risk of a structural re-rating from growth-SaaS to legacy-utility if capital costs outpace their ability to defend margins."
Claude and Grok are missing the capital allocation risk. At 2.9x sales, Waystar isn't just fighting AI commoditization; it's fighting its own balance sheet. If growth slows, the debt-to-EBITDA ratio will likely trigger a valuation floor drop, as the market stops valuing them as a high-growth SaaS and starts pricing them as a legacy utility. The 'moat' doesn't matter if the cost of capital exceeds the return on invested capital during this transition.
"Payer consolidation could actually strengthen Waystar's moat and renewals, making the 2.9x sales multiple less of a headwind than Gemini implies."
Pointing to 2.9x sales and debt risk misses the potential for payer consolidation to lock in longer renewals if Waystar's data moat translates into superior retention and price-upsell. The bigger flaw in Gemini's view is treating the balance sheet as the primary brake; even with leverage, a sticky ARR base could sustain multiples if growth holds. The real risk is a growth slowdown that amplifies capital-allocation concerns.
The panel consensus is bearish on Waystar (WAY) due to AI-driven margin compression, regulatory hurdles, and potential capital allocation risks. The stock's significant discount and slowdown in growth are seen as insufficient to offset these threats.
Payer consolidation potentially locking in longer renewals if Waystar's data moat translates into superior retention and price-upsell
AI-driven margin compression and potential capital allocation risks